Cargando…

Elevated Baseline C-Reactive Protein as a Predictor of Outcome After Aneurysmal Subarachnoid Hemorrhage: Data From the Simvastatin in Aneurysmal Subarachnoid Hemorrhage (STASH) Trial

There remains a proportion of patients with unfavorable outcomes after aneurysmal subarachnoid hemorrhage, of particular relevance in those who present with a good clinical grade. A forewarning of those at risk provides an opportunity towards more intensive monitoring, investigation, and prophylacti...

Descripción completa

Detalles Bibliográficos
Autores principales: Turner, Carole L., Budohoski, Karol, Smith, Christopher, Hutchinson, Peter J., Kirkpatrick, Peter J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neurosurgery 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4605277/
https://www.ncbi.nlm.nih.gov/pubmed/26280117
http://dx.doi.org/10.1227/NEU.0000000000000963
_version_ 1782395183507177472
author Turner, Carole L.
Budohoski, Karol
Smith, Christopher
Hutchinson, Peter J.
Kirkpatrick, Peter J.
author_facet Turner, Carole L.
Budohoski, Karol
Smith, Christopher
Hutchinson, Peter J.
Kirkpatrick, Peter J.
author_sort Turner, Carole L.
collection PubMed
description There remains a proportion of patients with unfavorable outcomes after aneurysmal subarachnoid hemorrhage, of particular relevance in those who present with a good clinical grade. A forewarning of those at risk provides an opportunity towards more intensive monitoring, investigation, and prophylactic treatment prior to the clinical manifestation of advancing cerebral injury. OBJECTIVE: To assess whether biochemical markers sampled in the first days after the initial hemorrhage can predict poor outcome. METHODS: All patients recruited to the multicenter Simvastatin in Aneurysmal Hemorrhage Trial (STASH) were included. Baseline biochemical profiles were taken between time of ictus and day 4 post ictus. The t-test compared outcomes, and a backwards stepwise binary logistic regression was used to determine the factors providing independent prediction of an unfavorable outcome. RESULTS: Baseline biochemical data were obtained in approximately 91% of cases from 803 patients. On admission, 73% of patients were good grade (World Federation of Neurological Surgeons grades 1 or 2); however, 84% had a Fisher grade 3 or 4 on computed tomographic scan. For patients presenting with good grade on admission, higher levels of C-reactive protein, glucose, and white blood cells and lower levels of hematocrit, albumin, and hemoglobin were associated with poor outcome at discharge. C-reactive protein was found to be an independent predictor of outcome for patients presenting in good grade. CONCLUSION: Early recording of C-reactive protein may prove useful in detecting those good grade patients who are at greater risk of clinical deterioration and poor outcome. ABBREVIATIONS: ALP, alkaline phosphatase ALT, alanine aminotransferase CK, creatine kinase CRP, C-reactive protein EVD, external ventricular drainage ICH GCP, International Conference on Harmonisation guidelines for good clinical practice mRS, modified Rankin Scale SAH, subarachnoid hemorrhage STASH, Simvastatin in Aneurysmal Subarachnoid Hemorrhage Trial WBC, white blood cells WFNS, World Federation of Neurological Surgeons
format Online
Article
Text
id pubmed-4605277
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Neurosurgery
record_format MEDLINE/PubMed
spelling pubmed-46052772015-10-29 Elevated Baseline C-Reactive Protein as a Predictor of Outcome After Aneurysmal Subarachnoid Hemorrhage: Data From the Simvastatin in Aneurysmal Subarachnoid Hemorrhage (STASH) Trial Turner, Carole L. Budohoski, Karol Smith, Christopher Hutchinson, Peter J. Kirkpatrick, Peter J. Neurosurgery Research—Human—Clinical Trials There remains a proportion of patients with unfavorable outcomes after aneurysmal subarachnoid hemorrhage, of particular relevance in those who present with a good clinical grade. A forewarning of those at risk provides an opportunity towards more intensive monitoring, investigation, and prophylactic treatment prior to the clinical manifestation of advancing cerebral injury. OBJECTIVE: To assess whether biochemical markers sampled in the first days after the initial hemorrhage can predict poor outcome. METHODS: All patients recruited to the multicenter Simvastatin in Aneurysmal Hemorrhage Trial (STASH) were included. Baseline biochemical profiles were taken between time of ictus and day 4 post ictus. The t-test compared outcomes, and a backwards stepwise binary logistic regression was used to determine the factors providing independent prediction of an unfavorable outcome. RESULTS: Baseline biochemical data were obtained in approximately 91% of cases from 803 patients. On admission, 73% of patients were good grade (World Federation of Neurological Surgeons grades 1 or 2); however, 84% had a Fisher grade 3 or 4 on computed tomographic scan. For patients presenting with good grade on admission, higher levels of C-reactive protein, glucose, and white blood cells and lower levels of hematocrit, albumin, and hemoglobin were associated with poor outcome at discharge. C-reactive protein was found to be an independent predictor of outcome for patients presenting in good grade. CONCLUSION: Early recording of C-reactive protein may prove useful in detecting those good grade patients who are at greater risk of clinical deterioration and poor outcome. ABBREVIATIONS: ALP, alkaline phosphatase ALT, alanine aminotransferase CK, creatine kinase CRP, C-reactive protein EVD, external ventricular drainage ICH GCP, International Conference on Harmonisation guidelines for good clinical practice mRS, modified Rankin Scale SAH, subarachnoid hemorrhage STASH, Simvastatin in Aneurysmal Subarachnoid Hemorrhage Trial WBC, white blood cells WFNS, World Federation of Neurological Surgeons Neurosurgery 2015-08-13 2015-11 /pmc/articles/PMC4605277/ /pubmed/26280117 http://dx.doi.org/10.1227/NEU.0000000000000963 Text en Copyright © 2015 by the Congress of Neurological Surgeons This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.
spellingShingle Research—Human—Clinical Trials
Turner, Carole L.
Budohoski, Karol
Smith, Christopher
Hutchinson, Peter J.
Kirkpatrick, Peter J.
Elevated Baseline C-Reactive Protein as a Predictor of Outcome After Aneurysmal Subarachnoid Hemorrhage: Data From the Simvastatin in Aneurysmal Subarachnoid Hemorrhage (STASH) Trial
title Elevated Baseline C-Reactive Protein as a Predictor of Outcome After Aneurysmal Subarachnoid Hemorrhage: Data From the Simvastatin in Aneurysmal Subarachnoid Hemorrhage (STASH) Trial
title_full Elevated Baseline C-Reactive Protein as a Predictor of Outcome After Aneurysmal Subarachnoid Hemorrhage: Data From the Simvastatin in Aneurysmal Subarachnoid Hemorrhage (STASH) Trial
title_fullStr Elevated Baseline C-Reactive Protein as a Predictor of Outcome After Aneurysmal Subarachnoid Hemorrhage: Data From the Simvastatin in Aneurysmal Subarachnoid Hemorrhage (STASH) Trial
title_full_unstemmed Elevated Baseline C-Reactive Protein as a Predictor of Outcome After Aneurysmal Subarachnoid Hemorrhage: Data From the Simvastatin in Aneurysmal Subarachnoid Hemorrhage (STASH) Trial
title_short Elevated Baseline C-Reactive Protein as a Predictor of Outcome After Aneurysmal Subarachnoid Hemorrhage: Data From the Simvastatin in Aneurysmal Subarachnoid Hemorrhage (STASH) Trial
title_sort elevated baseline c-reactive protein as a predictor of outcome after aneurysmal subarachnoid hemorrhage: data from the simvastatin in aneurysmal subarachnoid hemorrhage (stash) trial
topic Research—Human—Clinical Trials
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4605277/
https://www.ncbi.nlm.nih.gov/pubmed/26280117
http://dx.doi.org/10.1227/NEU.0000000000000963
work_keys_str_mv AT turnercarolel elevatedbaselinecreactiveproteinasapredictorofoutcomeafteraneurysmalsubarachnoidhemorrhagedatafromthesimvastatininaneurysmalsubarachnoidhemorrhagestashtrial
AT budohoskikarol elevatedbaselinecreactiveproteinasapredictorofoutcomeafteraneurysmalsubarachnoidhemorrhagedatafromthesimvastatininaneurysmalsubarachnoidhemorrhagestashtrial
AT smithchristopher elevatedbaselinecreactiveproteinasapredictorofoutcomeafteraneurysmalsubarachnoidhemorrhagedatafromthesimvastatininaneurysmalsubarachnoidhemorrhagestashtrial
AT hutchinsonpeterj elevatedbaselinecreactiveproteinasapredictorofoutcomeafteraneurysmalsubarachnoidhemorrhagedatafromthesimvastatininaneurysmalsubarachnoidhemorrhagestashtrial
AT kirkpatrickpeterj elevatedbaselinecreactiveproteinasapredictorofoutcomeafteraneurysmalsubarachnoidhemorrhagedatafromthesimvastatininaneurysmalsubarachnoidhemorrhagestashtrial
AT elevatedbaselinecreactiveproteinasapredictorofoutcomeafteraneurysmalsubarachnoidhemorrhagedatafromthesimvastatininaneurysmalsubarachnoidhemorrhagestashtrial